Background: Anti-vascular endothelial growth factor (VEGF) drugs are an option for the treatment of retinopathy of prematurity (ROP). Blocking of other angiogenic factors is also of interest. We therefore investigated in which effects would result blocking of placental growth factor (PlGF).
Methods: C57BL/6 mice were exposed to 75% oxygen from P7 to P12. Intravitreal injections were performed at P12. Mice of control groups remained untouched after oxygen treatment, or phosphate buffered saline or neutral IgG molecules were injected. In the treatment groups, antibodies against VEGF or PlGF, a mixture of anti-VEGF and anti-PlGF, aflibercept or sunitinib were injected. On P17, electroretinographic (ERG) measurements were performed. Avascular zones and neovascularization were evaluated in retinal flatmounts. Results are expressed as percent of total retinal area (median with median absolute deviation, MAD).
Results: Eyes of control groups showed similar neovascularization (1.4-3.3%, MAD 0.4-0.9%). Neovascularization was significantly less (0.5-0.7%, MAD 0.1-0.3%) in all treatment groups. Avascular zones in the retinas of control groups showed similar values (18.3-25 .7%, MAD 4.8-8.8%). Avascular zones were significantly reduced down to 3.6 AE 1.3% after anti-VEGF injection, but they were not reduced significantly in the other treatment groups (13.3-22%, MAD 3.6-6.1%). ERG measurements did not reveal significant differences between the controls and the treatment groups.
Conclusions: Blocking of PlGF or injection of sunitinib results in a similar inhibition of neovascularization as by anti-VEGF treatment in the mouse model of ROP. However, physiological angiogenesis that occurs after anti-VEGF treatment is blocked by anti-PlGF or sunitinib treatment, indicating that pathological neovascularization may follow different pathways than physiological angiogenesis.
INTRODUCTION
Retinopathy of prematurity (ROP) is a frequently occurring complication in preterm infants that have been kept in an atmosphere with enhanced oxygen pressure. 1, 2 Excess of oxygen may halt physiological angiogenesis, leading to a non-vascularized periphery of the retina. After the return of the infants to ambient atmosphere, missing supply with oxygen may lead to neovascularization, haemorrhages, retinal detachment and even blindness.
For many years, laser treatment has been the 'gold standard' in infants suffering from ROP. 3, 4 Although vascular endothelial growth factor (VEGF) had been identified as a key player in neovascularization, anti-VEGF treatment has been met with scepticism in the beginning. 5, 6 Nevertheless, anti-VEGF medication was increasingly applied during the last years, in particular by using bevacizumab and ranibizumab that have been already used in other neovascular diseases in the back of the eyes since the last 10 years. 7 Although anti-VEGF treatment of ROP showed considerable success, there are still open questions. It is not clear which side effects intravitreally injected anti-VEGF drugs have, as development of the vasculature may not be completed in all inner organs of the preterm infants and it is known that intravitreally injected drugs find their way into the systemic blood circulation, which could lead, for example, to adverse outcomes regarding the nervous system or myocardial malfunction. In a number of cases, anti-VEGF injection has to be repeated. In addition, some questions about the long-term outcome compared to conventional laser treatment are still not answered, for example, about development of myopia, vascular changes or size of the visual field, and stage of ROP has also to be considered. [8] [9] [10] Besides a more detailed evaluation of the questions listed above, it is of great interest if there are other growth factors than VEGF that are involved in pathological neovascularization in the course of ROP, and if their inhibition would have an additional effect on preventing neovascularization.
Out of several growth factors known to be involved in neovascularization, we chose placental growth factor (PlGF) that acts via the VEGF receptor 1, also known as Flt-1. In their review, Cavallaro et al. pointed to antiapoptotic function of PlGF during hyperoxia and a potential role of PlGF in neovascularization. 11 Moreover, Zhou et al. reported that PlGF expression was increased by anti-VEGF treatment in the OIR model, which suggests that an antiPlGF treatment might be useful if an anti-VEGF therapy is performed. 12 Therefore, we checked in the mouse model of ROP if blocking of PlGF shows some effects on neovascularization. For this purpose, we injected an anti-PlGF antibody intravitreally in mouse pups treated with oxygen. For comparison, we also injected an anti-VEGF antibody and a mixture of antibodies against VEGF and PlGF, and aflibercept, which is known to bind both VEGF and PlGF. 13 In a next experimental group, we treated the eyes with sunitinib which inhibits a number of receptor tyrosine kinases (PDGFR-α and -β, VEGFR-1, -2 and -3, KIT, FLT3, CSF-1R and RET), this way blocking many signal pathways linked to neovascularization and serving as a positive control.
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METHODS

Animals
We used wild-type C57BL6J mice for our study. 
Experimental protocol
The protocol was performed according to the general procedure published, for example, by Connor et al.
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The mouse pups were given with their mother into a chamber (Biospherix, Ltd., Parish, NY, USA) with an atmosphere enriched with oxygen (75%) at day P7 and remained there for 5 days. No more than seven pups per mother were given into the oxygen chamber in order to allow sufficient feeding of the pups and to avoid overload of the mother animal under the condition of oxygen-rich atmosphere. Moreover, we only took pups of at least 3.6 g body weight at day P7 for our experiments. On day P12, the animals were brought back to ambient air, and intravitreal injections were performed in both eyes. The pups were anaesthetized by a mixture of oxygen and 2 vol% isoflurane, lids were opened by forceps, and a local anaesthesia of the eyes was performed by a drop of proparacaine. Solutions of antibodies against VEGF or PlGF, a mixture of both antibodies, aflibercept in its commercial formulation as Eylea (Bayer Healthcare, Leverkusen, Germany) or a solution of sunitinib were injected intravitreally in the mouse pups. As negative controls, eyes without injections after oxygen treatment were used. In additional negative control groups, phosphate buffered saline (PBS, pH 7.4) was injected, or a solution of an IgG molecule that does not bind to any proteins in the mouse eye. As such a 'neutral' antibody, we chose an antibody against the green fluorescent protein (GFP) that does not occur in the mouse and therefore is not expected to exhibit specific effects in the living mouse eye. As the anti-VEGF antibody was the isotype IgG1 and the anti-PlGF antibody the isotype IgG2, we also used two different anti-GFP antibodies of both isotypes. The injection volume was 1 μL in each case. Both eyes of each mouse were treated the same way in order to avoid that a compound gone into systemic circulation from one eye would exert any influence on the other eye. All experimental groups including the compounds used for the injections are listed in Table 1 .
Electroretinography
Photopic electroretinographic measurements were performed on day P17. Pups were anaesthetized by an intraperitoneal injection of ketamine/xylazine. Pupils were dilated by a drop of tropicamide. Corneal anaesthesia was achieved by a drop of proparacaine. Body temperature of the mice was maintained constant at 37 C by a heated platform. Photopic electroretinographic (ERG) measurements were performed using the RetiPort device (Roland Consult, Brandenburg, Germany). Firstly, Ganzfeld flash ERG were recorded at four different light intensities 
Histology
After ERG measurements, pups were decapitated and eyes enucleated. The retina was isolated and stained with Isolectin B4 conjugated with the fluorescent dye Cy3 to label blood vessels. Digital images of retinal whole-mounts were taken with a fluorescent microscope (EVOS fl, Advanced Microscopy Group) and mounted and evaluated using Adobe Photoshop CS6 (Adobe Systems, Inc., San José, CA, USA). The read-outs for our study were the size of avascular zones (i.e. non-vascularized area of the retina) and the extent of the neovascularization. Total areas of retinal flat-mounts and avascular zones were determined by encircling them with the 'lasso' tool. Neovascularization areas were selected by the 'magic wand' tool. The number of pixels of the selected areas and therefore size values of all three parameters were obtained from the histogram window.
Statistics
Results for neovascularization and avascular zones are expressed as percent of total retinal area and given as median values with median absolute deviation. As we did not expect a Gaussian distribution of the data, statistical analysis of histological data as well as of electroretinographic amplitudes was done using the Kruskal-Wallis test and Dunn's multiple comparison (Prism 6, GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
General outcome
Intravitreal injections were well tolerated by the mouse pups, and there has been not a single case of an endophthalmitis or similar adverse event. In some of the animals, we abstained of intravitreal injection because of poor response towards isoflurane anaesthesia or due to unexpected problems, for instance due to strong bleeding because a retrobulbar blood vessel was hit. Blood vessels, sites of neovascularization and avascular zones could be easily recognized on retinal whole- 
Extent of neovascularization
Eyes untouched after oxygen treatment showed in general a high extent of neovascularization at P17, though with a high level of variation (median 2.6% of retinal area). A similar extent of neovascularization was found after intravitreal injection of the neutral antibodies (isotypes IgG1 and IgG2, 2.8% and 3.3%, respectively). After injection of PBS, neovascularization showed a clear trend to be of a lower extent (1.4%), without reaching statistically significant difference compared to other negative controls. A clear and statistically highly significant decrease of the extent of neovascularization was achieved by every of the anti-angiogenic treatments (0.5-0.7%). The results are summarized in the diagram shown in Figure 2 .
Sizes of avascular zones
When analysed at P12, immediately after oxygen treatment, large avascular zones were present in the retinas (not shown). Avascular zones remained large in all four groups of negative controls till analysis at P17 (18-26% of retinal area). In contrast to the findings regarding extent of neovascularization, the size of avascular zone after PBS injection was in the same range as in the other negative control groups. After injection of the anti-VEGF antibody, size of avascular zone was decreased clearly and with a high statistical significance (3.6%). After injection of the anti-PlGF antibody (without or with anti-VEGF antibody) sizes of avascular zones were found to be decreased only slightly compared to the negative controls (13% or 15%, respectively). Avascular zones were in the same range as the negative controls after injection of aflibercept or sunitinib (22% or 20%, respectively). The results are summarized in the diagram shown in Figure 3 . In order to visualize the relationship between extent of neovascularization and size of the avascular zones more clearly, we plotted the data presented above in a two-dimensional way (see diagram in Fig. 4 ). Whereas treatment with the anti-VEGF antibody alone shows unique effects (both neovascularization and avascular zones reduced very clearly), the other anti-angiogenic treatments, although showing a clear reduction of neovascularization, did not result in a notable reduction of avascular zones. Data points of negative controls are situated clearly in the region of a bigger extent of neovascularization and large avascular zones, with the PBS group showing a weaker neovascularization.
Electroretinography
Amplitudes of photopic ERG a-waves and b-waves as well as of photopic oscillatory potentials were clearly smaller in P17 pups treated with oxygen than in untreated P17 pups (Fig. 5) . A mentionable, although not significant, increase of the amplitudes of photopic ERG a-waves and b-waves was found in eyes where VEGF or PlGF were blocked as well in the eyes treated with PBS. In measurements of photopic oscillatory potentials and 30-Hz-Flicker-ERG, no obvious differences were found between the groups (not shown).
DISCUSSION
Besides treatment by laser, anti-angiogenic treatment by intravitreal injection of anti-VEGF agents is increasingly applied in preterm infants with retinopathy of prematurity; mainly in zone I stage 3+ cases. The outcome of anti-VEGF treatment is quite good, with respect to both suppression of neovascularization and re-vascularization of avascular zones. However, there are differences in efficacy of anti-VEGF treatment, depending on ROP stage and general state of the retina. This sometimes requires repeated treatment. Moreover, possible side effects of anti-VEGF drugs when entering systemic circulation are still disputed.
In this study, we investigated the effects of inhibition of another potentially pro-angiogenic growth factor, the placental growth factor (PlGF). Compared to VEGF, there is limited knowledge about occurrence and the role of PlGF. Therefore, it was of great There was no statistically significant difference within the groups of the negative controls and within the groups undergoing anti-angiogenic treatment, and also not between negative controls and groups with anti-angiogenic treatment, except for the anti-VEGF group as indicated in the diagram. Asterisks stand for P values: **P < 0.01, ***P < 0.001, ****P < 0.0001. Table below the diagram gives non-parametric P values of the statistical difference between the negative controls and the groups undergoing antiangiogenic treatment. There was no statistically significant difference between the PBS group and any other group as well as between the other negative controls or between the groups undergoing anti-angiogenic treatment. In the table, asterisks stand for P values: *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001.
interest to investigate the effects of PlGF inhibition in the experimental model of ROP and to compare it with the effects of VEGF inhibition.
The major result of our study was that only inhibition of VEGF alone resulted in an inhibited neovascularization with simultaneous almost complete restoration of retinal vasculature within the time of experiment. Inhibition of PlGF or general blocking of receptor tyrosine kinases by sunitinib also showed a reasonable inhibition of neovascularization, however, physiological angiogenesis appears to be impaired or even blocked during the time of experiment, as avascular zones remained almost as big as in the negative controls.
There are already some other experimental studies where aflibercept was applied in the experimental model of ROP. Lutty et al. applied aflibercept in the dog and achieved a clear reduction of neovascularization. 17 They used three different doses of aflibercept, and vascularized area of the retina decreased with increasing dose of aflibercept. Tokunaga et al. used two different doses of aflibercept in the ROP model in the mouse and reported about larger avascular areas compared to PBS injection in a dose-dependent manner. 18 Vähätupa et al. also described an increased avascular zone after application of aflibercept in the mouse model of ROP. 19 It has to be mentioned that the experimental protocols in these three studies differed slightly from each other and also from our protocol, and still there were the same results -clearly inhibited neovascularization and a larger remaining avascular zone when aflibercept was applied. Nevertheless, inhibition of physiological angiogenesis by aflibercept clearly is dose-dependent, as was also emphasized by McLeod and Lutty. 20 Obviously, doses of antiPlGF antibody or aflibercept used in our study were at such a high level that they blocked physiological angiogenesis, as it also was the case in the study of Vähätupa et al. 19 Similarly, Zhou et al. also injected an anti-PlGF antibody in the mouse ROP model and found, besides a clear reduction of neovascularization, a weaker reduction of the avascular zone than after anti-VEGF treatment. 12 Their results correspond to ours, as in our hands anti-PlGF treatment also gave a clear reduction of neovascularization, and avascular zones were also larger than after anti-VEGF treatment and smaller than in the negative controls or after treatment with sunitinib or aflibercept.
VEGF was shown to be needed for physiological angiogenesis. 21 This leads to the question why regular vascularization occurs if most of the VEGF has been neutralized, and why an excess of VEGF leads to pathological neovascularization instead of a regular vascularization. One admittedly speculative answer could be that in the case of excessive VEGF expression the 'blood vessel-growing capacity' of the retina completely operates 'at full capacity' to perform pathological neovascularization. If the amount of VEGF is very low due to an anti-VEGF treatment and only PlGF is present, then there is no stimulus for pathological neovascularization, and the retina gets its chance to grow a (more or less) regular vascular network. In this context, a synergy between PlGF and VEGF may be of importance, that is, that PlGF may increase the effectiveness of VEGF towards angiogenesis/neovascularization by occupying binding site of VEGFR-1, shifting the binding of VEGF to VEGFR-2. 22, 23 This way, physiological vascularization is possible in the presence of PlGF even at very low levels of VEGF. Influence of PlGF leads to the formation of stable and regular blood vessels, whereas VEGF may induce vascular leakage, 'daughter' vessels, glomeruloid bodies and arteriovenous malformations, which are all known from pathological neovascularization. 24 Thus, presence of PlGF may be helpful or even needed to establish a normal vascular network in the retina, which is corroborated by the finding that angiogenesis is impaired if PlGF is blocked. Synergy between VEGF and PlGF can also serve to explain inhibition of pathological neovascularization if PlGF is blocked alone.
We have no explanation for the slight but clearly visible reduction of neovascularization when PBS was injected intravitreally. Sunitinib and most of the antibodies were diluted in PBS, also the 'neutral' IgG1 and IgG2 molecules. Notably, also Vähä-tupa et al. reported about the anti-angiogenic effects of PBS injection, which even reached significance in their hands. 19 No stringent conclusions can be drawn from the ERG measurements, although there was a slight trend towards better amplitudes when VEGF or PlGF were blocked. This slight increase was seen in both a-wave amplitudes, indicating a better photoreceptor function, and b-wave amplitudes. Whereas an improved retinal function appears to be reasonable when VEGF is blocked (reduced neovascularization and avascular zones, i.e. a better blood supply), better retinal function is difficult to explain in the case of PlGF blockade where avascular zones remain larger. Full retinal functionality as detected by ERG is present in mice only at P24 to P28, as found in a previously performed series of measurements (P.H., unpublished). Therefore, besides the technical challenge with the small P17 pups, performing ERG measurements at P17 may be too early, and it may be useful to perform such measurements at a later time point in a future study.
There are two main conclusions from our results. Firstly, pathological neovascularization in the model of ROP and physiological angiogenesis appear to follow different pathways. Whereas both VEGF and PlGF seem to be necessary for pathological neovascularization, blocking of VEGF alone does not inhibit physiological angiogenesis, as was obvious by the drastically reduced size of avascular zones. In contrast, physiological angiogenesis appears to be blocked considerably when PlGF is blocked, or if a more general blocking of receptors is done by sunitinib. Secondly, it may be speculated that intravitreal injections of anti-VEGF drugs performed so far in preterm infants possibly could not be dangerous for the infants if anti-VEGF drugs do not block physiological angiogenesis when reaching systemic circulation. This hypothesis has to be investigated in future studies.
A limitation of our study is that we did not use different doses of anti-angiogenic drugs. In a previous study, we injected intravitreally 1 μL of commercial Avastin solution in mice, and we estimated that bevacizumab concentration in the vitreous was approximately 7.5 times higher than after an Avastin injection in a patient. 25 Although the concentration of foreign protein in the vitreous may be regarded to be very high, we found no structural damage and no functional impairment compared to PBS injection as checked by electroretinography. 25 Similar doses of antibodies were also applied in other studies, as also other groups used the antibody solutions as supplied by the commercial provider. In our study, we applied 40 μg of aflibercept per eye. Tokunaga et al. applied 2.5 μg or 10 μg aflibercept 18 , and Vähä-tupa et al. 20 μg aflibercept per eye. 19 As for antibodies, we injected a dose between 0.2 μg and 1.0 μg per eye. In other studies regarding the experimental ROP model in mice, Jo et al. injected 1 μg anti-VEGF antibody, 26 Zhu et al. 0.1-1.0 μg anti-IL-17A antibody, 27 Feng et al. 1.25-2.5 μg bevacizumab, 28 12 To our best knowledge, no other effects on retinal structure and integrity besides reduced neovascularization and (in some cases) an enhanced extent of physiological vascularization were reported.
Dosage of sunitinib applied in our study (0.5 μg sunitinib per eye) was also comparable to other studies, although not in studies about retinal neovascularization. Dib et al. tested toxicity of sunitinib in rabbit eyes and found no damage when 1.25 mg per eye was applied. 31 Ko et al. applied a dose of 250 μg for subconjunctival injections in rabbits, and used a solution of 0.5 mg/mL for topical application. 32 Hashemian et al. injected sunitinib under the conjunctiva of mice, and the doses were 0.2, 0.4 or 1.0 μg.
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It may be assumed that the doses used in our present study were overwhelmingly high, blocking most of VEGF and/or PlGF, or receptor tyrosine kinases in the case of sunitinib usage. It is possible that administration of smaller doses of antiangiogenic agents still would lead to a significantly reduced extent of neovascularization. As an example, Lorenz et al. reported on clinical cases where in preterm infants only a quarter of the bevacizumab dose was used instead of the half dose as usual, and they observed similar effectiveness of treatment. 34 As both Tokunaga et al. and McLeod and Lutty found dose-dependence of influence of aflibercept on the sizes of avascular zones, it is possible that a smaller dose of sunitinib, anti-PlGF antibody or aflibercept in our study would allow a better physiological angiogenesis in the retina, and hence a smaller avascular zone. 18, 20 Salman and Said reported on aflibercept administration in preterm infants with high-risk pre-threshold type 1 retinopathy and claimed, besides a complete regression of retinal neovascularization, that the eyes reached a full vascularization within 6-8 weeks after injection. 35 This finding is difficult to compare with those obtained in our study and the other experimental studies, as the time scale is much shorter in animal experiments, and in particular the mouse retina is spontaneously re-vascularized 2 or 3 weeks after oxygen treatment.
The data presented in this study show quite high deviations. One reason can be that intravitreal injections in mouse pups are difficult to perform in such small eyes. Certain differences between the animals can result from different numbers of pups per litter and, consequently, different feeding and different growth rate. Moreover, when the animals were taken out of the oxygen chamber and returned to ambient atmosphere to perform intravitreal injections, the injections could not be performed simultaneously in all pups of the litter, but in one after one, resulting in a time difference between the first and the last pup of 60 to 90 min. At the moment, we do not know what importance the exact duration between returning to ambient air and the intravitreal injection has. Finally, treatment with oxygen has also a variable effect on preterm infants in humans, and so it can also happen in the mouse pups, despite all efforts on standardization.
The results of our study suggest that physiological angiogenesis and pathological neovascularization may follow different pathways in the experimental model of retinopathy of prematurity. It seems that in contrast to PlGF, VEGF alone is not sufficient for physiological angiogenesis. On the other side, both PlGF and VEGF seem to be needed for pathological neovascularization. It has to be discovered in detail why avascular zones remain in the retina without an anti-angiogenic treatment, whereas physiological angiogenesis becomes possible when neovascularization is blocked by anti-VEGF treatment.
